The next "explosion point" of biomedicine may appear in Shenzhen. "China's pharmaceutical innovation ranks first in the second echelon in the world in terms of the quantitative indicators of R&D pipelines and listed new drugs." A few days ago, Song Ruilin, executive president of China Pharmaceutical Innovation Promotion Association, held the "Star of the Bay Area" biomedical source innovation conference in Shenzhen, and believed that China's pharmaceutical research and industrial development were entering a new stage of innovation. Chen Qiyu, vice president of China Pharmaceutical Innovation Promotion Association and executive director and co-CEO of Fosun International, said that Shenzhen has great advantages and development momentum in linking Greater Bay Area's urban development and AI technology. By leveraging the resources in the Bay Area and making good use of these advantages, it is possible to find a new fulcrum in the future biomedical R&D innovation track, and the next "explosion point" of biomedicine is likely to appear in Shenzhen.Ma Huateng: Contributing to the economic recovery, Ma Huateng said in People's Daily that Tencent, as a digital technology enterprise, actively responded to the deployment of the country to expand domestic demand and actively explored the development of digital consumption. By optimizing consumer tools such as WeChat payment, the company tries to create and serve effective demand and promote economic cycle by testing the e-commerce business such as live delivery of water video numbers. At the same time, Tencent relies on the WeChat ecosystem to enhance the absorption and friendliness of employment and entrepreneurship. Last year, it provided employment income opportunities for more than 50 million people. In the future, Tencent will also increase investment, devote itself to technological innovation and industrial upgrading, and jointly contribute to the stable and healthy development of China's economy with the vast number of private enterprises. (People's Network)The trading of traditional Chinese medicine has increased the daily limit of Panlong Pharmaceutical, the trading of traditional Chinese medicine has increased, Panlong Pharmaceutical has increased its daily limit, Xiangxue Pharmaceutical has increased by over 9%, and Kunyao Group, Weikang Pharmaceutical, Huasen Pharmaceutical and Xinguang Pharmaceutical have followed suit.
Beijing Haidian Joy City will open on December 21st. According to WeChat official account news of "Beijing Haidian" WeChat, Haidian Joy City, the fourth joy city in Beijing, will open on December 21st. At present, many brands have come to an end, and the merchants in the venue have entered the preparations for opening. It is understood that Haidian Joy City is expected to introduce more than 280 brands.The project of Chuangpu Instrument Industrial Park started in Hefei, with a total investment of 320 million yuan. According to the news of Hefei High-tech Zone Management Committee, on December 10th, the project of Chuangpu Instrument Industrial Park at the intersection of Caihong West Road and Peacock Terrace Road in Hefei High-tech Zone officially started. The total investment of the project is 320 million yuan, which is planned to be completed at one time and is expected to be put into use in the second half of 2027.Consumer stocks in Hong Kong stocks fluctuated higher, with the same journey rising by more than 6%, Mengniu Dairy rising by more than 4%, and China Resources Beer, Master Kong Holdings and Haidilao rising.
PETER LAMELAS was nominated by Trump as the US ambassador to Argentina.The Nikkei 225 index closed at 39,881.10 points in early trading, up 1.29%.In the concept of ice and snow economy, there were many daily limit changes, such as iceberg cold and hot, iceberg cold and hot, Longjian shares and Jingxue energy-saving daily limit, and Dalian Shengya, Changbai Mountain, Yeti shares and Sante ropeway were among the top gainers.
Strategy guide
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14
Strategy guide